TransThera Sciences (Nanjing) (FRA:J8J) Common Stock: €48.13 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8J TransThera Sciences (Nanjing) Inc FRA:J8J
20 GF Score
Price €1.05
! 2 Warning Signs
View Full Analysis

What is TransThera Sciences (Nanjing) Common Stock?

TransThera Sciences (Nanjing) FRA:J8J -0.94% 20 Common Stock is €48.13 Mil as of Dec. 2025. GuruFocus rates FRA:J8J with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

TransThera Sciences (Nanjing)'s quarterly common stock declined from Dec. 2024 (€50.06 Mil) to Jun. 2025 (€47.92 Mil) but then increased from Jun. 2025 (€47.92 Mil) to Dec. 2025 (€48.13 Mil).

TransThera Sciences (Nanjing)'s annual common stock increased from Dec. 2023 (€49.01 Mil) to Dec. 2024 (€50.06 Mil) but then declined from Dec. 2024 (€50.06 Mil) to Dec. 2025 (€48.13 Mil).

TransThera Sciences (Nanjing) Common Stock Historical Data

* Premium members only.

The historical data trend for TransThera Sciences (Nanjing)'s Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransThera Sciences (Nanjing) Common Stock Chart

TransThera Sciences (Nanjing) Annual Data
Trend Dec23 Dec24 Dec25
Common Stock
49.01 50.06 48.13

TransThera Sciences (Nanjing) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock 49.01 0.00 50.06 47.92 48.13
FRA:J8J
20GF Score
TransThera Sciences (Nanjing) Inc FRA:J8J
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransThera Sciences (Nanjing) Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €48.13 Mil mean?
TransThera Sciences (Nanjing) (FRA:J8J) has a Common Stock of €48.13 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on TransThera Sciences (Nanjing) and its competitors.
Is TransThera Sciences (Nanjing)'s Common Stock too high?
TransThera Sciences (Nanjing)'s current Common Stock is €48.13 Mil. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s Common Stock compare to VRTX and REGN?
TransThera Sciences (Nanjing)'s Common Stock of €48.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on TransThera Sciences (Nanjing) and its competitors. TransThera Sciences (Nanjing)'s current Common Stock is €48.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (FRA:J8J) has a current Common Stock of €48.13 Mil. The current Common Stock is €48.13 Mil. TransThera Sciences (Nanjing)'s overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (FRA:J8J), the current Common Stock is €48.13 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransThera Sciences (Nanjing) Business Description

Other Exchanges 02617:Hong Kong
Address Biotech and Pharmaceutical Valley, 3rd floor, Building 9, Accelerator Phase 2, Jiangbei New Area, Jiangsu Province, Nanjing, CHN, 210032
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
20GF Score

Get the complete analysis for FRA:J8J

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.05
Price